Published in Blood on January 13, 2010
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood (2011) 1.54
Safer CARS. Mol Ther (2010) 1.46
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood (2012) 1.22
Relapse after allogeneic stem cell transplantation. Expert Rev Hematol (2010) 1.14
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol (2011) 1.14
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant (2013) 1.13
Chemoimmunotherapy. Cancer J (2010) 1.13
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Genetic modification of T cells. Biol Blood Marrow Transplant (2011) 1.10
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica (2015) 1.02
Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat Commun (2014) 1.01
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther (2011) 0.97
Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet (2011) 0.97
Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Haematologica (2012) 0.95
Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Leukemia (2012) 0.91
Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells. Biol Blood Marrow Transplant (2011) 0.91
Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica (2012) 0.90
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. Leuk Lymphoma (2013) 0.88
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica (2012) 0.88
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia (2014) 0.86
Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol (2010) 0.85
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One (2011) 0.84
Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy. Am J Reprod Immunol (2013) 0.84
Immunotherapy for pediatric leukemia. Front Oncol (2013) 0.84
Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia (2011) 0.83
Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection. J Proteome Res (2014) 0.82
Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol (2016) 0.82
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol (2015) 0.82
Treatment of acute myeloid leukemia in the elderly. Haematologica (2011) 0.81
Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.81
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther (2017) 0.80
T lymphocytes targeting native receptors. Immunol Rev (2014) 0.80
Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy. Hum Vaccin Immunother (2013) 0.80
Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells. Biol Blood Marrow Transplant (2013) 0.80
Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. Bone Marrow Transplant (2015) 0.79
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proc Natl Acad Sci U S A (2012) 0.78
Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation. Transplantation (2015) 0.78
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol (2012) 0.77
Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. J Transl Med (2015) 0.77
Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival. Bone Marrow Transplant (2013) 0.76
Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunol Immunother (2013) 0.76
Combating cancer with allogeneic T cells. Blood (2010) 0.75
Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol (2016) 0.75
Cellular therapy following allogeneic stem-cell transplantation. Ther Adv Hematol (2011) 0.75
HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation. Leukemia (2016) 0.75
Adoptive Immunotherapy for Leukemia with Ex Vivo Expanded T Cells. Curr Drug Targets (2015) 0.75
Requirement of CD4 help for induction of CD8 T cell response specific for virally derived h60. Immune Netw (2012) 0.75
Identification and isolation of antigen-specific cytotoxic T lymphocytes with an automated microraft sorting system. Integr Biol (Camb) (2016) 0.75
TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease. Immune Netw (2017) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood (2004) 3.05
Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 2.65
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol (2002) 2.18
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A (1999) 1.93
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother (2005) 1.91
Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med (2001) 1.88
HapMap scanning of novel human minor histocompatibility antigens. Blood (2008) 1.75
Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev (1997) 1.74
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol (2000) 1.49
Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood (1998) 1.49
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet (2007) 1.41
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood (2009) 1.39
Bone marrow transplantation: a review. Semin Hematol (1999) 1.25
Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood (1999) 1.23
Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol (1998) 1.10
Minors come of age: Minor histocompatibility antigens and graft-versus-host disease. Biol Blood Marrow Transplant (2004) 1.04
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood (2008) 1.01
Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol (2004) 0.86
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res (2005) 11.02
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 7.00
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Efficacy of communication skills training for giving bad news and discussing transitions to palliative care. Arch Intern Med (2007) 5.23
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 4.52
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Frequent inactivation of A20 in B-cell lymphomas. Nature (2009) 4.22
Multiple mutations and cancer. Proc Natl Acad Sci U S A (2003) 4.21
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 4.02
AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med (2004) 4.00
Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell (2003) 3.91
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A (2006) 3.11
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood (2009) 3.05
Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med (2010) 3.01
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Notch1 but not Notch2 is essential for generating hematopoietic stem cells from endothelial cells. Immunity (2003) 2.94
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol (2011) 2.89
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol (2002) 2.74
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 2.65
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood (2010) 2.61
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell (2012) 2.53
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.49
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Implementing a Death with Dignity program at a comprehensive cancer center. N Engl J Med (2013) 2.38
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood (2003) 2.33
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol (2004) 2.28
AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle. J Biol Chem (2006) 2.24
Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes (2006) 2.24
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood (2013) 2.23
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell (2006) 2.20
An antigen produced by splicing of noncontiguous peptides in the reverse order. Science (2006) 2.18
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 2.15
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood (2012) 2.11
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood (2002) 2.11
Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol (2006) 2.09
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem (2003) 2.07
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol (2010) 2.07
Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell (2008) 2.05
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood (2010) 2.05
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood (2010) 2.01
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood (2012) 2.00
Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 2.00
Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift. Diabetes (2007) 1.98
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
Acute myeloid leukemia. J Natl Compr Canc Netw (2012) 1.96
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci (2009) 1.95
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med (2004) 1.92
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood (2012) 1.85
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol (2010) 1.84
MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med (2007) 1.83
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood (2002) 1.80
Benchmarks in clinical productivity: a national comprehensive cancer network survey. J Oncol Pract (2007) 1.79
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest (2002) 1.79
Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood (2013) 1.79